Reni Benjamin
Stock Analyst at Citizens Capital Markets
(1.35)
# 3,295
Out of 4,784 analysts
183
Total ratings
35.95%
Success rate
-14.71%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.34 | +190.61% | 9 | Mar 31, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $13.77 | - | 9 | Mar 18, 2025 | |
| ALLO Allogene Therapeutics | Upgrades: Market Outperform | $5 | $1.45 | +244.95% | 7 | Mar 14, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $60.09 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $0.81 | - | 5 | Mar 7, 2025 | |
| BPMC Blueprint Medicines | Reiterates: Market Outperform | $125 | $87.43 | +42.97% | 21 | Mar 3, 2025 | |
| BCYC Bicycle Therapeutics | Reiterates: Market Outperform | $26 | $8.53 | +204.81% | 13 | Feb 26, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $0.98 | +308.16% | 5 | Jan 14, 2025 | |
| CUE Cue Biopharma | Maintains: Market Outperform | $15 → $2 | $0.91 | +119.78% | 4 | Jul 26, 2024 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.50 | +166.67% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $4.23 | - | 4 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.47 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $6.22 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $16 | $0.20 | +7,856.24% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $19.09 | -47.62% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $5 | $1.60 | +213.48% | 5 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.71 | - | 10 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $4.94 | +62.11% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $0.81 | +390.98% | 4 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $53.01 | +13.19% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $32 | $19.46 | +64.48% | 2 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $10.55 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $230.05 | +36.93% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $71.80 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $225.62 | +17.45% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $6.73 | +316.36% | 9 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $6 | $1.25 | +380.00% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $17.72 | - | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $25 → $23 | $3.35 | +587.59% | 10 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $3.49 | +387.80% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.30 | - | 3 | Nov 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $6.98 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.25 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $38.43 | -68.77% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $11.02 | - | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.29 | - | 2 | Nov 10, 2017 |
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.34
Upside: +190.61%
Inhibrx Biosciences
Mar 18, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $13.77
Upside: -
Allogene Therapeutics
Mar 14, 2025
Upgrades: Market Outperform
Price Target: $5
Current: $1.45
Upside: +244.95%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $60.09
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.81
Upside: -
Blueprint Medicines
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $125
Current: $87.43
Upside: +42.97%
Bicycle Therapeutics
Feb 26, 2025
Reiterates: Market Outperform
Price Target: $26
Current: $8.53
Upside: +204.81%
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $0.98
Upside: +308.16%
Cue Biopharma
Jul 26, 2024
Maintains: Market Outperform
Price Target: $15 → $2
Current: $0.91
Upside: +119.78%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.50
Upside: +166.67%
Nov 12, 2020
Upgrades: Market Perform
Price Target: n/a
Current: $4.23
Upside: -
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.47
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $6.22
Upside: -
Oct 22, 2018
Maintains: Outperform
Price Target: $20 → $16
Current: $0.20
Upside: +7,856.24%
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $19.09
Upside: -47.62%
Mar 18, 2025
Upgrades: Market Outperform
Price Target: $5
Current: $1.60
Upside: +213.48%
Mar 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.71
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $4.94
Upside: +62.11%
Mar 12, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $0.81
Upside: +390.98%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $53.01
Upside: +13.19%
Feb 25, 2025
Reiterates: Market Outperform
Price Target: $32
Current: $19.46
Upside: +64.48%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $10.55
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $230.05
Upside: +36.93%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $71.80
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $225.62
Upside: +17.45%
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $6.73
Upside: +316.36%
Dec 11, 2024
Downgrades: Market Perform
Price Target: $6
Current: $1.25
Upside: +380.00%
Nov 4, 2024
Initiates: Market Perform
Price Target: n/a
Current: $17.72
Upside: -
Jun 20, 2024
Maintains: Market Outperform
Price Target: $25 → $23
Current: $3.35
Upside: +587.59%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $3.49
Upside: +387.80%
Nov 15, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $0.30
Upside: -
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $6.98
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.25
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $38.43
Upside: -68.77%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $11.02
Upside: -
Nov 10, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $2.29
Upside: -